Pharma BD Deal Intelligence

Valeant Pharmaceuticals International / Biovail Corporation

2010 · Acquisition/Merger · $3.3B · Complete

Announcement Sentiment

Neutral / mixed

Valeant and Biovail entered merger-of-equals with Biovail acquiring Valeant. Valeant stockholders received $16.77/share special dividend + 1.7809 Biovail shares. Combined company renamed Valeant Pharmaceuticals International. Closed September 28, 2010.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Accretive

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Jun 21, 2010
Closed Sep 28, 2010
Deal value $3.3B
Deal type Acquisition/Merger
Therapeutic area CNS/neurology; specialty pharma
Indications CNS/neurology; specialty pharma
Key assets Wellbutrin XL; specialty CNS portfolio
Mechanism Mixed (specialty pharma portfolio)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals